Exousia Pro CSO Revealed Significant Findings About the Glioblastoma Study in a Spaces Interview
Exousia Pro (OTC PINK:MAJI) has shared significant findings regarding their Glioblastoma (GBM) study. Chief Science Officer Dr. Marvin Hausman revealed in a Spaces interview that published research demonstrates the effectiveness of NANOG Expression therapy in treating GBM cells.
The research showed that while temozolomide (TMZ) alone at maximum concentration eliminated less than 20% of GBM cells, combining TMZ with shRNA targeting NANOG or OCT4 significantly increased cell death rates. This combination therapy proved particularly effective at reducing the resistance of Cancer stem cells in Glioblastoma.
Exousia Pro (OTC PINK:MAJI) ha condiviso risultati importanti riguardo al loro studio sul Glioblastoma (GBM). Il Chief Science Officer, Dr. Marvin Hausman, ha rivelato in un'intervista su Spaces che ricerche pubblicate dimostrano l'efficacia della terapia con espressione di NANOG nel trattamento delle cellule GBM.
Lo studio ha evidenziato che mentre la temozolomide (TMZ) da sola, alla massima concentrazione, eliminava meno del 20% delle cellule GBM, la combinazione di TMZ con shRNA mirati a NANOG o OCT4 ha aumentato significativamente i tassi di morte cellulare. Questa terapia combinata si è dimostrata particolarmente efficace nel ridurre la resistenza delle cellule staminali tumorali nel Glioblastoma.
Exousia Pro (OTC PINK:MAJI) ha compartido hallazgos importantes sobre su estudio del Glioblastoma (GBM). El Director Científico, Dr. Marvin Hausman, reveló en una entrevista en Spaces que investigaciones publicadas demuestran la efectividad de la terapia de expresión de NANOG en el tratamiento de células GBM.
La investigación mostró que mientras la temozolomida (TMZ) sola, en concentración máxima, eliminaba menos del 20% de las células GBM, la combinación de TMZ con shRNA dirigidos a NANOG u OCT4 aumentó significativamente las tasas de muerte celular. Esta terapia combinada resultó especialmente eficaz para reducir la resistencia de las células madre cancerosas en el Glioblastoma.
Exousia Pro (OTC PINK:MAJI)는 교모세포종(GBM) 연구에 관한 중요한 발견을 공유했습니다. 최고 과학 책임자인 Dr. Marvin Hausman은 Spaces 인터뷰에서 발표된 연구가 NANOG 발현 치료가 GBM 세포 치료에 효과적임을 보여준다고 밝혔습니다.
연구 결과, 최대 농도의 테모졸로마이드(TMO) 단독 투여 시 GBM 세포의 20% 미만만 사멸되었으나, NANOG 또는 OCT4를 표적으로 하는 shRNA와 TMZ를 병용하면 세포 사멸률이 크게 증가하는 것으로 나타났습니다. 이 병용 치료는 교모세포종 내 암 줄기세포의 저항성을 줄이는 데 특히 효과적이었습니다.
Exousia Pro (OTC PINK:MAJI) a partagé des résultats importants concernant leur étude sur le Glioblastome (GBM). Le Directeur scientifique, Dr Marvin Hausman, a révélé lors d’une interview sur Spaces que des recherches publiées démontrent l’efficacité de la thérapie par expression de NANOG dans le traitement des cellules GBM.
La recherche a montré que, tandis que la témozolomide (TMZ) seule, à concentration maximale, éliminait moins de 20 % des cellules GBM, la combinaison de TMZ avec des shRNA ciblant NANOG ou OCT4 augmentait significativement les taux de mort cellulaire. Cette thérapie combinée s’est avérée particulièrement efficace pour réduire la résistance des cellules souches cancéreuses dans le Glioblastome.
Exousia Pro (OTC PINK:MAJI) hat bedeutende Erkenntnisse zu ihrer Glioblastom-(GBM-)Studie veröffentlicht. Der Chief Science Officer, Dr. Marvin Hausman, erklärte in einem Spaces-Interview, dass veröffentlichte Forschungen die Wirksamkeit der NANOG-Expressions-Therapie bei der Behandlung von GBM-Zellen belegen.
Die Forschung zeigte, dass Temozolomid (TMZ) allein in maximaler Konzentration weniger als 20 % der GBM-Zellen abtötete, die Kombination von TMZ mit shRNA, die auf NANOG oder OCT4 abzielt, jedoch die Zellsterberate deutlich erhöhte. Diese Kombinationstherapie erwies sich als besonders effektiv, um die Resistenz von Krebsstammzellen im Glioblastom zu verringern.
- Published research validates the effectiveness of company's NANOG Expression therapy
- Significant improvement in cancer cell death rates when combining NANOG/OCT4 targeting with traditional treatment
- Technology shows promise in overcoming resistance in Glioblastoma treatment
- None.
A published paper shows NANOG Expression was almost
ORLANDO, FL / ACCESS Newswire / April 21, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in the treatment of cancer and other diseases, is pleased to share published information about the therapy being used in our current Glioblastoma ("GBM") study.
Dr. Marvin Hausman, our Chief Science Officer, revealed Thursday live on a Spaces interview that a paper had been published showing that the NANOG Expression therapy reduced the resistance of the Cancer stem cells in Glioblastoma. In fact, the paper goes on to reveal that when temozolomide ("TMS") was used on its own at its highest concentration, less than
The full paper may be read here: https://pmc.ncbi.nlm.nih.gov/articles/PMC10297980/
Matt Dwyer, our President, stated, "I was listening to the Spaces interview and couldn't believe what I was hearing. I had no clue this information existed. I know the current study and its findings, but this was mind-blowing. I suggest everyone go listen to Dr. Hausman and pay attention to the excitement in his voice as he discusses the ongoing study."
About Us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology.The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Marijuana Inc.
View the original press release on ACCESS Newswire
FAQ
What are the key findings of MAJI's Glioblastoma treatment study?
How effective is MAJI's NANOG Expression therapy for Glioblastoma treatment?
What is the mechanism behind MAJI's Glioblastoma treatment?
What progress has MAJI made in their clinical-stage Glioblastoma research?
